Hyperkalemia is prevalent in patients on hemodialysis and poses risks of hospitalization and mortality2,3
Despite receiving in-center hemodialysis, 38% of patients presented at US dialysis centers in August 2019 with hyperkalemia (n=7938)*2
In a retrospective observational study, where hyperkalemia was deﬁned as K+ ≥5.5 mEq/L
Prevalence of hyperkalemia was found to be 2.4x higher in hemodialysis patients during the day after the long interdialytic interval vs the day after the short interdialytic interval†4
The short interdialytic interval was deﬁned as a single day between sessions.
The long interdialytic interval was deﬁned as multiple days between sessions.
*Data from the DOPPS Practice Monitor using the most recent (single) monthly pre-dialysis values of serum K+ levels from the national sample of >11,000 patients in >200 US hemodialysis centers. Note: Hyperkalemia is deﬁned as K+ ≥ 5.0 mEq/L. Timing of K+ measurement in relation to the hemodialysis schedule, whether after a long or short interdialytic interval, is unknown.2
†A retrospective observational study from the USRDS of hemodialysis patients (N=36,888) during 2010 with ≥6 hemodialysis sessions and ≥1 K+ measurement. Serum K+ was typically measured once a month during routine sessions. The hemodialysis schedule was 3 times weekly.4
‡Rate of hyperkalemia was computed as a ratio of total number of hyperkalemia episodes and cumulative follow-up time in months. The LIDI rate was calculated based on hyperkalemia episodes identified on the day after the LIDI and the SIDI rate was calculated based on hyperkalemia episodes identified on the day after the SIDI.4
DOPPS=Dialysis Outcomes and Practice Patterns Study; HK=hyperkalemia; LIDI=long interdialytic interval; SIDI=short interdialytic interval; USRDS=United States Renal Data System.
In a retrospective observational study of ESRD patients receiving thrice-weekly hemodialysis (n=52,734), serum K+ ≥5.5 mEq/L was associated with increased adjusted risk of all-cause hospitalization*5
HYPERKALEMIA IS ASSOCIATED WITH AN INCREASED RISK OF ALL-CAUSE AND CV MORTALITY IN PATIENTS RECEIVING HEMODIALYSIS†3
Graph reproduced from Torlén et al. 2012.
LOKELMA® (sodium zirconium cyclosilicate) is not indicated to reduce the risk of death or hospitalizations.1
*Based on an analysis of 533,889 qualifying serum K+ measurements from US Medicare adult patients at a large dialysis organization with at least 1 K+ measurement between January 2010 and December 2011. Serum K+ measurements were generally performed monthly immediately prior to HD on the ﬁrst or second treatment day after the long weekend (ie, Monday or Wednesday for a Monday-Wednesday-Friday schedule). Analyses were adjusted for covariates including demographics, comorbidities, and laboratory values.5
†Analysis of 111,434 hemodialysis patients with follow-up data from an observational cohort study conducted in US DaVita facilities between July 2001 and June 2006. Hyperkalemia deﬁned as K+ ≥5.0 mEq/L. The timing of K+ measurement in relation to the hemodialysis cycle and schedule was not described in the study. Data was adjusted for demographics, comorbidities, and laboratory values.3
‡Reference group was hemodialysis patients with serum K+ between 4.0 and 4.5 mEq/L.3
§Each patient had K+ measurements performed at least monthly. The average of all repeated measures was done quarterly for 20 calendar quarters to calculate the time-averaged serum K+.3
CV=cardiovascular; ESRD=end-stage renal disease; HD=hemodialysis.